NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of “Moderate Buy” by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has received a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $36.75.

A number of analysts recently commented on the stock. BTIG Research restated a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Ascendiant Capital Markets reaffirmed a “buy” rating and set a $48.00 price target (up previously from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. D. Boral Capital reiterated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC bought a new stake in NRx Pharmaceuticals in the 3rd quarter valued at $39,000. Sjbenen Advisory LLC acquired a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at about $41,000. One Wealth Management Investment & Advisory Services LLC raised its stake in shares of NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the period. Two Sigma Investments LP lifted its holdings in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the period. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Trading Down 2.3%

NASDAQ:NRXP opened at $2.12 on Tuesday. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $3.84. The firm has a market capitalization of $62.75 million, a price-to-earnings ratio of -0.90 and a beta of 1.62. The business’s 50-day moving average price is $2.31 and its two-hundred day moving average price is $2.68.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. Sell-side analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.